Navigation Links
NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
Date:3/3/2008

SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the initiation of two large clinical pharmacology studies in the United States, which will assess the blood pressure profile of naproxcinod in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique. These separate studies, 12 and 16 weeks in duration, will together recruit a total of around 420 osteoarthritis patients with controlled hypertension and results are projected in Q4 2008. Naproxcinod is NicOx' lead investigational drug and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is currently in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis, with results of the last two phase 3 studies anticipated in the second half of 2008.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen and naproxen, are commonly used by osteoarthritis patients to control their chronic pain, inflammation and stiffness and significantly improve quality of life for millions of people. However, these important products have the tendency to raise blood pressure to an extent that may increase the rate of serious cardiovascular adverse events (see NOTE 1).

Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: "Our development program for naproxcinod aims to address the safety concerns surrounding anti-inflammatory agents and blood pressure, which represents a serious medical issue. Previous studies using the ABPM technique and Office Blood Pressure Measurements have suggested that naproxcinod may have an improved blood pressure profile compared to existing anti-inflammatory drugs, which would greatly facilitate its future adoption by physicians and patients. These two new studies will provide important data in a relevant population of chronically treated osteoa
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
2. NicOx Opens U.S. Headquarters in New Jersey
3. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers.  B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... PharmAthene, Inc.,(Amex: PIP ) a biodefense ... announced that the Delaware Chancery Court,today issued a ... dismiss,PharmAthene,s complaint, which alleges that it has a ... SIGA,s drug candidate, SIGA-246. SIGA,s,request to dismiss the ...
... Helix BioPharma Corp.,(TSX: HBP/Frankfurt: WKN 918846) announced today ... Inc. ("KBI") to develop a process for,preparing L-DOS47 ... clinical testing., "This new arrangement advances the ... with L-DOS47," said John Docherty, Helix,s,president. "The lyophilized ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) will announce ... on Thursday, January 31. During a 10 a.m. (ET) ... information and will,address inquiries from investors and analysts., ... to a live,webcast of the call at http://www.bms.com/ir ...
Cached Biology Technology:Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthene's Legal Action in Breach of Contract Lawsuit Against SIGA 2Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format 2Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format 3
(Date:4/24/2014)... at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified the ... to discriminate between viral and endogenous RNAs in ... take control of cellular metabolism and hijack cellular ... process is dependent on viral RNA molecules that ... RNA viruses) and/or newly synthesized in the host ...
(Date:4/24/2014)... With a new generation of military veterans returning home ... become a prominent concern in American medical institutions and ... 35 percent of personnel deployed to Iraq and Afghanistan ... South Carolina School of Medicine is shedding light on ... and surprising ways. , The rise in PTSD has ...
(Date:4/23/2014)... pair of bioethics experts have added "playwright" to their ... in grappling with an onslaught of ethical issues as ... the human genome was first sequenced. , Until ... W. Bush have been performed for, and by, their ... conferences, meetings and in classrooms. With Oxford University ...
Breaking Biology News(10 mins):Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3New study links inflammation in those with PTSD to changes in microRNA 2New study links inflammation in those with PTSD to changes in microRNA 3Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3
... For the first time, neuroscientists have systematically identified the ... communications network that supports brain function. Their work, ... in Human Neuroscience , has major implications for understanding ... have the greatest influence over all other connections, the ...
... 10, 2014In a study published today in ... Ken Shepard, professor of electrical engineering and biomedical ... professor of biological sciences at Columbia University, has ... modern computers and communications devices, can be used ...
... Feb. 10, 2014 The Translational Genomics Research Institute (TGen) ... to the brain, according to a first-of-its-kind study published in ... of genetic targets uncovered by TGen now can be used ... therapies for the estimated 45,000 patients in the U.S. each ...
Cached Biology News:How our brain networks: Research reveals white matter 'scaffold' of human brain 2How our brain networks: Research reveals white matter 'scaffold' of human brain 3Chips that listen to bacteria 2TGen study uncovers possible genetic markers in breast cancer that spreads to the brain 2
... the Adept CE 4100 high pressure dual piston ... wavelength detector for added flexibility. The ... and interface unit, CE 4901., The CE 4901 ... be used with Windows 98 and 2000, offers ...
...
... Chromosomal Grade Agarose was developed specifically for pulsed field separations of DNA larger than 2, ... megabase pairs. This ... ... Megabase DNA separations done in Chromosomal Grade, ...
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Biology Products: